solo para uso en investigación
Cat. No.: S1949
Estructura química
| Líneas celulares | Tipo de ensayo | Concentración | Tiempo de incubación | Formulación | Descripción de la actividad | PMID |
|---|---|---|---|---|---|---|
| HT22 cells | Function assay | Neuroprotective activity in mouse HT22 cells assessed as prevention from glutamate-induced oxidative cell death by MTS assay, PD50=0.797 μM | ||||
| HeLa cell | Cytotoxicity assay | Cytotoxicity against HeLa cell lines, EC50=3.7 μM | ||||
| PaCa2 cell | Proliferation assay | Antiproliferative activity against human pancreatic carcinoma Mia PaCa2 cell line by colorimetric assay, IC50=6.2 μM | ||||
| HT-29 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay, IC50=9.69 μM | |||
| DU145 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay, IC50=9.86 μM | |||
| MDA-MB-231 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay, IC50=12.68 μM | |||
| human A2058 cells | Cytotoxicity assay | Cytotoxicity against human A2058 cells assessed as inhibition of formazan formation at day 5 by measuring absorbance at 430 nm, IC50=13.4 μM | ||||
| SAS cells | Cytotoxicity assay | 48 h | Cytotoxicity against human SAS cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50=14 μM | |||
| HaCaT cells | Function assay | 48 h | Antihyperproliferative activity against human HaCaT cells assessed as inhibition of cell growth after 48 hrs by phase contrast microscopy, IC50=15.8 μM | |||
| HeLa cells | Cytotoxicity assay | 48 h | Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50=18 μM | |||
| CRL2796 cells | Cytotoxicity assay | Cytotoxicity against human CRL2796 cells assessed as inhibition of formazan formation at day 4 by measuring absorbance at 430 nm, IC50=21 μM | ||||
| HL60 cells | Function assay | 50 μM | Induction of necrosis in intact human HL60 cells assessed as cytosolic LDH release at 50 uM | |||
| Haga clic para ver más datos experimentales de líneas celulares | ||||||
| Peso molecular | 172.18 | Fórmula | C11H8O2 |
Almacenamiento (Desde la fecha de recepción) | 3 years-20°C(in the dark) powder |
|---|---|---|---|---|---|
| Nº CAS | 58-27-5 | Descargar SDF | Almacenamiento de soluciones madre |
|
|
| Sinónimos | NSC 4170 | Smiles | CC1=CC(=O)C2=CC=CC=C2C1=O | ||
|
In vitro |
DMSO
: 34 mg/mL
(197.46 mM)
Ethanol : 34 mg/mL Water : Insoluble |
|
In vivo |
|||||
Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)
Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)
Resultados del cálculo:
Concentración de trabajo: mg/ml;
Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH2O, mezclar y clarificar.
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.
Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.
| Targets/IC50/Ki |
Cdc25 phosphatase
DNA polymerase γ
|
|---|---|
| In vitro |
Menadione (Vitamin K3) prevents mitochondrial Ca(2+) uptake in normal pancreatic acinar cells, which permits rapid spread of Ca(2+) throughout the cell. Its-induced mitochondrial depolarisation is due to induction of the permeability transition pore. At nontoxic concentration, this compound results in a brief activation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) in the RALA255-10G rat hepatocyte cell line. It is equipotent against multidrug-resistant and parental leukemia cell lines with IC50 values of 13.5 mM and 18 mM, respectively. The compound inhibits the incorporation of radioactive thymidine, uridine and amino acids into DNA, RNA and protein, respectively, in three humancancer cell lines. At 1-20 mM, it dose- and time-dependently inhibits cell proliferation of AR4-2J cells. A concentration of 100 mM causes rapid cell death. This level (100 mM) induces DNA smear in electrophoresis indicative of necrosis, while lower concentrations (10-20 mM) induces a DNA ladder indicative of apoptosis. Concentrations of 1-20 mM induce wild-type P53, whereas 100 mM has a minor effect on wild-type P53. Treatment with it clearly affects the mitochondrial function of Jurkat T cells by inducing a collapse of the inner transmembrane potential (DeltaPsi(m)) and a decrease in inner membrane mass, which could be completely reversed by N-acetylcysteine. |
Referencias |
|
| Métodos | Biomarcadores | Imágenes | PMID |
|---|---|---|---|
| Western blot | p-JNK / JNK / p-c-Jun / c-Jun / p-ERK / ERK Cyclin B1 / CDK1 / CDC25C c-Fos / HO-1 |
|
20578144 |
(datos de https://clinicaltrials.gov, actualizado el 2024-05-22)
| Número NCT | Reclutamiento | Condiciones | Patrocinador/Colaboradores | Fecha de inicio | Fases |
|---|---|---|---|---|---|
| NCT01094444 | Completed | Folliculitis |
Per Pfeiffer|Odense University Hospital |
May 2010 | Phase 2 |
| NCT00656786 | Completed | EGFR Inhibitor-associated Rash |
Spectrum Pharmaceuticals Inc |
April 3 2008 | Phase 1 |